# Temsirolimus and Cetuximab in Patients With Advanced or Metastatic Solid Tumors

> **NCT02215720** · PHASE1 · COMPLETED · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 45 (actual)

## Conditions studied

- Patients With Advanced or Metastatic Solid Tumors

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** Temsirolimus

## Key facts

- **NCT ID:** NCT02215720
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04-26
- **Primary completion:** 2014-09-15
- **Final completion:** 2016-05-04
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02215720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02215720, "Temsirolimus and Cetuximab in Patients With Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-07-24 from https://api.ai-analytics.org/clinical/NCT02215720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*